Healthcare entity
Every one of those 1 sits in a single category, market-trends. Collegium Pharmaceutical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 12 original sources per story, versus 4.7 across the same-window beat baseline.
Last mentioned: Feb 26, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, market-trends. Collegium Pharmaceutical is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Source depth averages 12 original sources per story, versus 4.7 across the same-window beat baseline. Their average consequence score of 5 runs below the beat's 5.6 for that window. Intellia Therapeutics appears in 1 tracked Healthcare story from February 26, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 41 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Intellia Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
The Q4 2025 earnings cycle for mid-cap healthcare highlights a strategic shift from clinical validation to commercial execution across gene editing, radiopharmaceuticals, and digital health. While platform innovators like Intellia and Kymera advance toward pivotal milestones, commercial leaders like Lantheus and Vericel are demonstrating the durability of high-barrier therapeutic markets.
Intellia Therapeutics is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
